Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Early recognition of anti-N-methyl D-aspartate (Nmda) receptor encephalitis presenting as acute psychosis|
|Citation:||Australasian Psychiatry, 2013; 21(6):596-599|
|Publisher:||Informa Healthcare-Taylor & Francis|
|Jessica Tidswell, Timothy Kleinig, David Ash, Philip Thompson, Cherrie Galletly|
|Abstract:||OBJECTIVE: We present a case of anti-N-methyl D-aspartate (NMDA) receptor encephalitis that illustrates the dilemma that psychiatrists face in evaluating patients with first episode psychosis. CONCLUSIONS: The discovery that acute psychosis can be the presenting feature of autoimmune encephalitis (in particular encephalitis caused by anti-NMDA receptor antibodies) has both practical and theoretical consequences. First, this condition is an important, but often overlooked, differential diagnosis of first episode psychosis. Antibody testing is not currently part of routine screening, though delayed (or missed) diagnosis can lead to prolonged hospital stay, medical complications and incomplete or delayed recovery. Widespread screening of patients with first presentation psychosis for anti-NMDA receptor and anti-voltage-gated potassium channel (anti-VGKC) antibodies is warranted for a number of reasons: to expedite appropriate treatment, to determine the true proportion of patients with these conditions presenting as psychosis, and to help elucidate the neurochemical causes of psychosis.|
|Keywords:||anti-N-methyl D-aspartate receptor encephalitis; first episode psychosis|
|Rights:||© The Royal Australian and New Zealand College of Psychiatrists 2013|
|Appears in Collections:||Pathology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.